Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
AMO Pharma has reached agreement with the FDA, UK MHRA, and Health Canada on the design of a registrational study for AMO-02 (oral tideglusib) in congenital myotonic dystrophy type 1 (cDM1). The pivotal trial will use hospitalization as its primary endpoint, backed by long-term safety data showing a low hospitalization rate and no deaths or cardiovascular events. A study launch update is expected in Q3 2026.
AMO Pharma has secured regulatory alignment with the FDA, UK MHRA, and Health Canada on the design of a registrational study for AMO-02 (oral tideglusib), an investigational treatment for congenital myotonic dystrophy type 1 (cDM1) — a rare, inherited neuromuscular disorder affecting muscle function, cognition, development, and cardiac health. The agreed-upon primary endpoint is hospitalization, supported by multiple functional assessments as secondary measures. An update on study initiation is expected in Q3 2026.
The hospitalization endpoint is grounded in data from REACHCDM-X, the longest-running interventional study in cDM1, which logged a hospitalization rate of just 0.14 events per patient per year across 151+ patient-years of exposure, with no deaths or cardiovascular events. These findings helped inform the endpoint choice after the earlier REACH-CDM trial missed its clinician-rated primary endpoint — though it did show significant benefits in cognition, muscle biomarkers, and a composite functional score.
Key Takeaways:
Why it matters: Congenital DM1 has no approved treatments, and regulatory agreement on a meaningful, disease-relevant endpoint like hospitalization is a critical step toward a potential therapy for this underserved patient population.
